Korean J Pediatr.  2011 May;54(5):192-196. 10.3345/kjp.2011.54.5.192.

Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey

• Jung JW

• KMID: 2284867
• DOI: http://doi.org/10.3345/kjp.2011.54.5.192

Abstract

Respiratory syncytial virus (RSV) is a main cause of hospitalization for bronchiolitis and pneumonia in infants worldwide. Children with hemodynamically significant congenital heart disease (HS-CHD), as well as premature infants are at high risk for severe RSV diseases. Mortality rates for CHD patients hospitalized with RSV have been reported as about 24 times higher compared with those without RSV infection. Recently with advances in intensive care, mortality rates in CHD patients combined with RSV have decreased below 2%. The requirements of intensive care and mechanical ventilation for CHD patients with RSV infection were still higher than those without RSV infection or with non-CHD children. RSV infection has frequently threatened CHD infants with congestive heart failure, cyanosis, or with pulmonary hypertension. As a progressive RSV pneumonitis in those infants develops, the impairment of oxygen uptake, the breathing workload gradually increases and eventually causes to significant pulmonary hypertension, even after the operation. Preventing RSV infection as much as possible is very important, especially in infants with HS-CHD. A humanized monoclonal antibody, palivizumab, has effective in preventing severe RSV disease in high-risk infants, and progressive advances in supportive care including pulmonary vasodilator have dramatically decreased the mortality (<1%). Depending on the global trend, Korean Health Insurance guidelines have approved the use of palivizumab in children <1 year of age with HS-CHD since 2009. Korean data are collected for RSV prophylaxis in infants with CHD.

Keyword

Respiratory syncytial virus; Congenital heart diseases; Pediatric

MeSH Terms

Antibodies, Monoclonal, Humanized
Bronchiolitis
Child
Cyanosis
Heart
Heart Diseases
Heart Failure
Hospitalization
Humans
Hypertension, Pulmonary
Infant
Infant, Newborn
Infant, Premature
Insurance, Health
Critical Care
Oxygen
Pneumonia
Respiration
Respiration, Artificial
Respiratory Syncytial Viruses
Palivizumab
Antibodies, Monoclonal, Humanized
Oxygen